Cargando…

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma in order to define markers of activity in the blood and tumor as assessed at baseline (before ipilimumab) and early on-treatment. Patients were treated with ipilimumab (10 mg/kg intravenously every...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarhini, Ahmad A., Edington, Howard, Butterfield, Lisa H., Lin, Yan, Shuai, Yongli, Tawbi, Hussein, Sander, Cindy, Yin, Yan, Holtzman, Matthew, Johnson, Jonas, Rao, Uma N. M., Kirkwood, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912016/ https://www.ncbi.nlm.nih.gov/pubmed/24498358 http://dx.doi.org/10.1371/journal.pone.0087705

Ejemplares similares

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

CD8+ T cell responses in metastatic melanoma patients receiving an adenovirally antigen engineered dendritic cell vaccine +/- IFN-α
por: Du, Samuel, et al.
Publicado: (2015)

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
por: Retseck, Janet, et al.
Publicado: (2016)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
por: Tarhini, Ahmad, et al.
Publicado: (2018)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
por: Najjar, Yana G., et al.
Publicado: (2017)

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
por: Butterfield, Lisa H., et al.
Publicado: (2019)

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature
por: Piña, Yolanda, et al.
Publicado: (2021)

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma
por: Slingluff, Craig L., et al.
Publicado: (2021)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

CD56(dim) CD16(−) Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
por: Vujanovic, Lazar, et al.
Publicado: (2019)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Targeted therapy in melanoma
por: Tawbi, Hussein, et al.
Publicado: (2009)

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
por: Knox, Susan, et al.
Publicado: (2014)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
por: Lowe, Devin B, et al.
Publicado: (2014)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
por: Tarhini, Ahmad A, et al.
Publicado: (2014)

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011)

Neoadjuvant therapy of locally/regionally advanced melanoma
por: Khunger, Arjun, et al.
Publicado: (2019)

Ipilimumab for advanced melanoma: A pharmacologic perspective
por: Trinh, Van Anh, et al.
Publicado: (2013)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Emerging options for the treatment of melanoma – focus on ipilimumab
por: Roddie, Claire, et al.
Publicado: (2014)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab
por: Kobeissi, Iyad, et al.
Publicado: (2023)

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
por: Feng, Yan, et al.
Publicado: (2014)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0rmh9knet616s9cu50u3tc9fl3